Rocket Pharmaceuticals (RCKT) Assets Average (2016 - 2025)
Historic Assets Average for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $394.5 million.
- Rocket Pharmaceuticals' Assets Average fell 608.11% to $394.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.5 million, marking a year-over-year decrease of 608.11%. This contributed to the annual value of $547.0 million for FY2024, which is 215.6% down from last year.
- According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Assets Average is $394.5 million, which was down 608.11% from $446.0 million recorded in Q2 2025.
- Rocket Pharmaceuticals' Assets Average's 5-year high stood at $583.7 million during Q1 2021, with a 5-year trough of $394.5 million in Q3 2025.
- For the 5-year period, Rocket Pharmaceuticals' Assets Average averaged around $493.7 million, with its median value being $488.3 million (2023).
- Per our database at Business Quant, Rocket Pharmaceuticals' Assets Average soared by 5671.26% in 2021 and then plummeted by 2091.79% in 2024.
- Rocket Pharmaceuticals' Assets Average (Quarter) stood at $513.6 million in 2021, then fell by 5.66% to $484.5 million in 2022, then rose by 20.23% to $582.6 million in 2023, then decreased by 20.92% to $460.7 million in 2024, then decreased by 14.37% to $394.5 million in 2025.
- Its Assets Average stands at $394.5 million for Q3 2025, versus $446.0 million for Q2 2025 and $499.4 million for Q1 2025.